|
1.
|
|
7 p, 518.4 KB |
Langerhans cell histiocytosis. Advances in pathogenesis and clinical practice Histiocitosis de células de Langerhans. Avances en la patogenia y práctica clínica
/
Astigarraga, Itziar (Universidad del País Vasco) ;
García-Obregón, Susana (Universidad del País Vasco) ;
Pérez-Martínez, Antonio (Instituto de Investigación del Hospital La Paz) ;
Gutiérrez-Carrasco, Ignacio (Hospital Infantil Virgen del Rocío) ;
Santa-María, Vicente (Hospital Sant Joan de Deu) ;
Rodríguez-Vigil Iturrate, Carmen (Hospital Universitario Miguel Servet) ;
Lorite Reggiori, Mikael (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Murciano Carrillo, Thais (Hospital Universitari Vall d'Hebron) ;
Torrent, Montse (Institut d'Investigació Biomèdica Sant Pau) ;
Universitat Autònoma de Barcelona
Langerhans cell histiocytosis (LCH) is a type of myeloid neoplasia that can affect different organs or tissues and exhibits substantial variability in its clinical presentation and biological behaviour, so it may mimic different diseases. [...]
2022 -  10.1016/j.anpedi.2022.05.002
Anales de pediatría, Vol. 97 Núm. 2 (agosto 2022) , p. 130.e1-130.e7
|
|
|
2.
|
|
12 p, 1.6 MB |
Validation of dynamic risk stratification and impact of BRAF in risk assessment of thyroid cancer, a nation-wide multicenter study
/
Pérez-Fernández, Laura (Hospital del Tajo) ;
Sastre, Julia (Hospital Universitario de Toledo) ;
Zafón, Carles (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Oleaga, Amelia (Hospital de Basurto (Bilbao, Biscaia)) ;
Castelblanco, Esmeralda (Hospital Arnau de Vilanova (València)) ;
Capel Flores, Ismael (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Galofré, Juan C. (Instituto de Investigación Sanitaria de Navarra) ;
Guadalix-Iglesias, Sonsoles (Hospital Universitario 12 de Octubre (Madrid)) ;
De la Vieja, Antonio (Instituto de Salud Carlos III) ;
Riesco-Eizaguirre, Garcilaso (Universidad Francisco de Vitoria) ;
Universitat Autònoma de Barcelona
The dynamic risk stratification (DRS) is a relatively new system in thyroid cancer that considers the response to primary treatment to improve the initial risk of recurrence. We wanted to validate DRS system in a nationwide multicenter study and explore if the incorporation of BRAFV600E into DRS helps to better categorize and predict outcomes. [...]
2023 - 10.3389/fendo.2022.1071775
Frontiers in Endocrinology, Vol. 13 (january 2023)
|
|
|
3.
|
|
16 p, 1.6 MB |
Genetic Determinants for Prediction of Outcome of Patients with Papillary Thyroid Carcinoma
/
Póvoa, Antónia Afonso (Universidade do Porto) ;
Teixeira, Elisabete (Universidade do Porto) ;
Bella-Cueto, Maria Rosa (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Batista, Rui (Universidade do Porto) ;
Pestana, Ana (Universidade do Porto) ;
Melo, Miguel (Centro Hospitalar Universitário de Coimbra) ;
Alves, Thalita (Universidade Federal de São Paulo) ;
Pinto, Mafalda (i3S-Instituto de Investigação e Inovação em Saúde) ;
Sobrinho-Simões, Manuel (Universidade do Porto) ;
Maciel, Jorge (Universidade Fernando Pessoa) ;
Soares, Paula (Universidade do Porto) ;
Universitat Autònoma de Barcelona
Aggressive metastatic disease is rare in papillary thyroid carcinoma (PTC), a neoplasia that usually carries an excellent prognosis. BRAF, RAS, and TERT promoter (TERTp) genes are altered in PTC, and their impact on patient outcomes remains controversial. [...]
2021 - 10.3390/cancers13092048
Cancers, Vol. 13 (april 2021)
|
|
|
4.
|
|
8 p, 712.6 KB |
Biomarker analysis beyond angiogenesis : RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study
/
Yoshino, Takayuki (National Cancer Center Hospital East, Kashiwa, Japan) ;
Portnoy, D. C. (The West Clinic, Memphis, USA) ;
Obermannová, R. (Masarykuv Onkologicky Ustav, Brno, Czech Republic) ;
Bodoky, G. (St László Hospital (Hongria)) ;
Prausová, J. (Fakultni Nemocnice v MOTOLE, Prague, Czech Republic) ;
García-Carbonero, Rocío (Hospital Universitario 12 de Octubre (Madrid)) ;
Ciuleanu, Tudor Eliade (Institutul Oncologic Ion Chiricuta and UMF Iuliu Hatieganu, Cluj-Napoca, Romania) ;
García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ;
Cohn, A. L. (Rocky Mountain Cancer Center, LLP, Denver, USA) ;
Van Cutsem, E. (University Hospitals Gasthuisberg (Leuven, Bélgica)) ;
Yamazaki, K. (Shizuoka Cancer Center, Shizuoka, Japan) ;
Lonardi, Sara (Istituto Oncologico Veneto-IRCCS, Padova, Italy) ;
Muro, K. (Aichi Cancer Center Hospital) ;
Kim, T. W. (Asan Medical Center, University of Ulsan, Seoul, Republic of Korea) ;
Yamaguchi, K. (The Cancer Institute Hospital of JFCR, Tokyo, Japan) ;
Grothey, A. (Mayo Clinic, Phoenix, USA) ;
O'Connor, J. (Instituto Alexander Fleming (Buenos Aires, Argentina)) ;
Taieb, Julien (Sorbonne Paris Cité, Paris Descartes University, Georges Pompidou European Hospital, Paris, France) ;
Wijayawardana, S. R. (Eli Lilly and Company, Indianapolis, USA) ;
Hozak, Rebecca R (Eli Lilly and Company, Indianapolis, USA) ;
Nasroulah, F. (Eli Lilly and Company, Buenos Aires, Argentina) ;
Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Vall d'Hebron Institut d'Oncologia
: Second-line treatment with ramucirumab+FOLFIRI improved overall survival (OS) versus placebo+FOLFIRI for patients with metastatic colorectal carcinoma (CRC) [hazard ratio (HR)=0. 84, 95% CI 0. 73-0. [...]
2018 - 10.1093/annonc/mdy461
Annals of oncology, Vol. 30 (october 2018) , p. 124-131
|
|
|
5.
|
|
20 p, 6.8 MB |
IKKα Kinase Regulates the DNA Damage Response and Drives Chemo-resistance in Cancer
/
Colomer, Carlota (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Margalef, Pol (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Villanueva, Alberto (Institut d'Investigació Biomèdica de Bellvitge) ;
Vert, Anna (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Pecharroman, Irene (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Solé Font, Laura (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Gonzàlez-Farré, Mònica (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Alonso, Josune (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Montagut, Clara (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Martinez-Iniesta, Maria (Institut d'Investigació Biomèdica de Bellvitge) ;
Bertran, Joan (Universitat de Vic - Universitat Central de Catalunya) ;
Borràs, Eva (Centre de Regulació Genòmica) ;
Iglesias, Mar (Universitat Autònoma de Barcelona. Departament de Ciències Morfològiques) ;
Sabidó, Eduard (Centre de Regulació Genòmica) ;
Bigas Salvans, Anna (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Boulton, Simon J. (The Francis Crick Institute) ;
Espinosa, Lluís (Institut Hospital del Mar d'Investigacions Mèdiques)
Phosphorylated IKKα(p45) is a nuclear active form of the IKKα kinase that is induced by the MAP kinases BRAF and TAK1 and promotes tumor growth independent of canonical NF-κB signaling. Insights into the sources of IKKα(p45) activation and its downstream substrates in the nucleus remain to be defined. [...]
2019 - 10.1016/j.molcel.2019.05.036
Molecular Cell, Vol. 75 (august 2019) , p. 669-682.e5
|
|
|
6.
|
|
13 p, 2.9 MB |
BRAF mutations classes I, II, and III in NSCLC patients included in the SLLIP trial : The need for a new pre-clinical treatment rationale
/
Bracht, Jillian (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Karachaliou, Niki (Hospital Universitari Sagrat Cor. Institut Oncològic Rosell) ;
Bivona, Trever (University of California. Department of Medicine) ;
Lanman, Richard B. (Guardant Health) ;
Faull, Iris (Guardant Health) ;
Nagy, Rebecca J. (Guardant Health) ;
Drozdowskyj, Ana (PIVOTAL SL) ;
Berenguer, Jordi (Institut Universitari Quirón-Dexeus. Laboratori de Biologia Molecular) ;
Fernandez-Bruno, Manuel (Hospital Universitario Sagrat Cor. Institut Oncològic Rosell) ;
Molina-Vila, Miguel Ángel (Institut Universitari Quirón-Dexeus. Laboratori de Biologia Molecular) ;
Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
BRAF V600 mutations have been found in 1-2% of non-small-cell lung cancer (NSCLC) patients, with Food and Drug Administration (FDA) approved treatment of dabrafenib plus trametinib and progression free survival (PFS) of 10. [...]
2019 - 10.3390/cancers11091381
Cancers, Vol. 11, Issue 9 (September 2019) , art. 1381
|
|
|
7.
|
|
10 p, 1.9 MB |
Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer
/
Codony-Servat, Jordi (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Cuatrecasas, Miriam ;
Asensio, Elena (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Montironi, Carla (Hospital Clínic i Provincial de Barcelona) ;
Martínez Cardús, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Marín Aguilera, Mercedes (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Horndler, Carlos (Hospital Universitario Miguel Servet (Saragossa)) ;
Martínez Balibrea, Eva (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Rubini, Michele (Department of Experimental and Diagnostic Medicine, University of Ferrara) ;
Jares, Pedro (Hospital Clínic i Provincial de Barcelona) ;
Reig, Oscar (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Victoria, Iván (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Gaba, Lydia (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Martín Richard, Marta (Institut d'Investigació Biomèdica Sant Pau) ;
Alonso, Vicente (Hospital Universitario Miguel Servet (Saragossa)) ;
Escudero, Pilar (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
Fernández-Martos, Carlos (Fundació Institut Valencià d'Oncologia) ;
Feliu, Jaime (Centro de Investigación Biomédica en Red de Cáncer) ;
Méndez, Jose Carlos (Centro Oncológico de Galicia) ;
Méndez, Miguel (Hospital Universitario de Móstoles (Madrid)) ;
Gallego, Javier (Hospital General Universitario de Elche) ;
Salud, Antonieta (Hospital Arnau de Vilanova (Lleida, Catalunya)) ;
Rojo, Federico (Fundacion Jimenez Diaz) ;
Castells, Antoni (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Prat, Aleix (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
García-Albéniz, Xabier (Harvard T.H. Chan School of Public Health (Boston, Estats Units d'Amèrica)) ;
Camps, Jordi (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Maurel, Joan (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Universitat Autònoma de Barcelona
Although chemotherapy is the cornerstone treatment for patients with metastatic colorectal cancer (mCRC), acquired chemoresistance is common and constitutes the main reason for treatment failure. Monoclonal antibodies against insulin-like growth factor-1 receptor (IGF-1R) have been tested in pre-treated mCRC patients, but results have been largely deceiving. [...]
2017 - 10.1038/bjc.2017.279
British Journal of Cancer, Vol. 117 (november 2017) , p. 1777-1786
|
|
|
8.
|
|
9 p, 435.9 KB |
Prediction of overall survival in stage II and III colon cancer beyond TNM system : a retrospective, pooled biomarker study
/
Dienstmann, Rodrigo. (Hospital Universitari Vall d'Hebron) ;
Mason, M. J. (Computational Oncology, Sage Bionetworks, Seattle, USA) ;
Sinicrope, F. A. (Mayo Clinic and Mayo Comprehensive Cancer Center, Rochester, USA) ;
Phipps, A. I. (Fred Hutchinson Cancer Research Center, Seattle, USA) ;
Tejpar, Sabine (University Hospitals Gasthuisberg (Leuven, Bélgica)) ;
Nesbakken, A. (Oslo University Hospital (Oslo, Noruega)) ;
Danielsen, S. A. (Oslo University Hospital (Oslo, Noruega)) ;
Sveen, A. (Oslo University Hospital (Oslo, Noruega)) ;
Buchanan, Daniel D (The University of Melbourne) ;
Clendenning, M. (The University of Melbourne) ;
Rosty, C. (The University of Melbourne) ;
Bot, Brian M (Computational Oncology, Sage Bionetworks, Seattle, USA) ;
Alberts, S. R. (Mayo Clinic and Mayo Comprehensive Cancer Center, Rochester, USA) ;
Milburn Jessup, J. (National Cancer Institute (Rockville, Estats Units d'Amèrica)) ;
Lothe, R. A. (Oslo University Hospital (Oslo, Noruega)) ;
Delorenzi, Mauro (SIB Swiss Institute Bioinformatics, Lausanne, Switzerland) ;
Newcomb, P. A. (Fred Hutchinson Cancer Research Center, Seattle, USA) ;
Sargent, D. (Mayo Clinic, Rochester, USA) ;
Guinney, J. (Computational Oncology, Sage Bionetworks, Seattle, USA) ;
Universitat Autònoma de Barcelona
TNM staging alone does not accurately predict outcome in colon cancer (CC) patients who may be eligible for adjuvant chemotherapy. It is unknown to what extent the molecular markers microsatellite instability (MSI) and mutations in BRAF or KRAS improve prognostic estimation in multivariable models that include detailed clinicopathological annotation. [...]
2017 - 10.1093/annonc/mdx052
Annals of oncology, Vol. 28 (february 2017) , p. 1023-1031
|
|
|
9.
|
|
9 p, 403.1 KB |
Correlation between mutational status and survival and second cancer risk assessment in patients with gastrointestinal stromal tumors : a population-based study
/
Rubió Casadevall, Jordi (Institut Català d'Oncologia) ;
Borràs, Joan Lluis (Hospital Universitari Sant Joan de Reus (Tarragona)) ;
Carmona-Garcia, M. Carmen (Institut d'Investigació Biomèdica de Girona) ;
Ameijide, Alberto (Universitat Rovira i Virgili. Fundació per a la Investigació i Prevenció del Càncer) ;
Gonzalez-Vidal, Allan (Institut d'Investigació Biomèdica Sant Pau) ;
Ortiz, Maria Rosa (Hospital Universitari de Girona Doctor Josep Trueta) ;
Bosch Príncep, Ramon (Hospital de Tortosa Verge de la Cinta) ;
Riu, Francesc (Hospital Universitari Sant Joan de Reus (Tarragona)) ;
Parada, David (Hospital Universitari Sant Joan de Reus (Tarragona)) ;
Martí, Esther (Hospital Sant Pau i Santa Tecla (Tarragona)) ;
Miró, Josefina (Clinica Girona Departament de Patologia) ;
Sirvent, Juan Jose (Hospital Universitari Joan XXIII de Tarragona) ;
Galceran, Jaume (Red Temática de Investigación Cooperativa en Cáncer (RTICC), Girona, Spain) ;
Marcos-Gragera, Rafael (Institut d'Investigació Biomèdica de Girona) ;
Universitat Autònoma de Barcelona
Gastrointestinal stromal tumors are sarcomas of the digestive tract characterized by mutations mainly located in the c-KIT or in the platelet-derived growth factor receptor (PDGFR)-alpha genes. Mutations in the BRAF gene have also been described. [...]
2015 - 10.1186/s12957-015-0474-0
World Journal of Surgical Oncology, Vol. 13 (february 2015)
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
